Medicare Part D
-
340B, Alzheimer’s, Caught my eye, CMMI, Drug Prices, Inflation Reduction Act, Medicaid, Medicare Advantage, Medicare Negotiation, Medicare Part D, Pharmacy Benefit Managers, Reference Pricing, State-based ReformAMP is WAC — 05/15/26
Read more: AMP is WAC — 05/15/26I have had two friends in the last week tell me stories about their health insurance experiences that make me angry about our healthcare system. As I write this, I’m sitting in a Senate building waiting to do a briefing for staff and I want to go office to office and ask – what are…
-
340B, Caught my eye, Cell and Gene, CMMI, Drug Prices, Drug shortages, Generics, Healthcare Costs, Medicaid, Medicare Part D, Obesity, Pharmacy Benefit Managers, Supply Chain, TariffsAMP is WAC — 5/1/26
Read more: AMP is WAC — 5/1/26As I was in Las Vegas this week, I kept pulling out my notebook and jotting down ideas for client work and projects. Having meetings, listening in on panels, fantastic dinner conversations – it was all so inspiring. Good to be away, good to be home. Feather in the Cap. On Monday, a new study…
-
Caught my eye, Cell and Gene, Drug Prices, DTC, Inflation Reduction Act, Medicare Part D, State-based Reform, UncategorizedAMP is WAC — 03/27/26
Read more: AMP is WAC — 03/27/26I’m supposed to be getting ready to take a few days off but I’m having trouble detaching. I’m so in the zone (and happy with it all) that the idea of stopping seems scary? Which absolutely means that I need to take a break, right?… No issue next week unless something big happens. Say Yes…
-
340B, Affordable Care Act, Alzheimer’s, Biosimilars, Cell and Gene, CMMI, FDA, Inflation Reduction Act, Medicare Part D, ObesityAMP is WAC — 03/13/26
Read more: AMP is WAC — 03/13/26The Bigger They Are, the Faster They Grow. A new white paper from Health Capital Group, sponsored by Johnson & Johnson, analyzed HRSA’s OPAIS database from 2017 through 2023 and found something many observers of the 340B program have suspected for years; size is the dominant variable. Hospitals in the top quartile by bed size…
-
340B, Caught my eye, Drug Prices, Inflation Reduction Act, Medicaid, Medicare Part D, Pharmacy Benefit ManagersAMP is WAC — 3/6/26
Read more: AMP is WAC — 3/6/26Can you ever feel sad looking at photo of a chimp wearing clothes? Maybe it will make the latest policy news go down just a little smoother. 340B’s Split Screen. February 26 brought two developments in the 340B contract pharmacy fight. They pointed in opposite directions. First, a judge in the Middle District of Tennessee…
-
Caught my eye, Inflation Reduction Act, Medicare Advantage, Medicare Part D, Orphan Drugs, Pharmacy Benefit ManagersAMP is WAC — 02/27/26
Read more: AMP is WAC — 02/27/26Next week I’m joining Cencora for a webinar (sign up), followed by presenting at Access USA in Philadelphia and then, off to Vegas, for Asembia. If you’ll be in Philly or Vegas, I’d welcome a conversation about what’s truly consequential right now and what isn’t. Coffee or Paper Planes (IYKYK) optional. Quieter week around here…
-
340B, Affordable Care Act, Biosimilars, Caught my eye, Drug Prices, Inflation Reduction Act, Insulin, Medicare Negotiation, Medicare Part D, Pharmacy Benefit Managers, State-based Reform, Utilization ManagementAMP is WAC — 2/13/26
Read more: AMP is WAC — 2/13/26I chuckled during the E&C hearing when members were questioning the panelists about the pharmaceutical deals with the Administration. As if these are the people they should be asking. Make a left, make right, go down about a mile – there’s a big white house. Maybe they can help you there. Parallels Between 340B and…
-
Caught my eye, Copay Accumulators, Drug Prices, Employers, Healthcare Costs, Insulin, Medicare Part D, Pharmacy Benefit Managers, Utilization ManagementAMP is WAC — 2/6/26
Read more: AMP is WAC — 2/6/26No, I do not think that a groundhog is a meteorologist. But, one year I am determined to make it to see Punxsutawney Phil. I expect it to be silly and cold and over quickly. I will likely have to go solo because my family thinks getting a bus from a Wal-mart parking lot in…
-
Affordable Care Act, Caught my eye, Drug Prices, DTC, Employers, Medicare Advantage, Medicare Part D, Pharmacy Benefit Managers, Reference Pricing, State-based Reform, Utilization ManagementAMP is WAC — 1/30/26
Read more: AMP is WAC — 1/30/26This week I had to remind myself that we live in the AND. Things can be truly awful around us, but there are still moments of happiness and hope. There are some periods in life where it is harder to find the AND, but it is there. At least that is what I have to…
-
340B, Caught my eye, CMMI, Drug Prices, FDA, Healthcare Costs, Inflation Reduction Act, Medicare Advantage, Medicare Negotiation, Medicare Part D, Orphan Drugs, Pharmacy Benefit Managers, Reference Pricing, ValueAMP is WAC — 1/16/26
Read more: AMP is WAC — 1/16/26In case you thought I’d leaving you hanging, today’s newsletter has a summary on GLOBE. Sphere it below? Calling it a Plan would be GENEROUS, but that’s a Whole Other Thing. On Thursday, the White House released a fact sheet urging Congress to enact President Trump’s “Great Healthcare Plan,” pitching it as a cost-cutting package…
Latest news
- AMP is WAC — 05/22/26
- AMP is WAC — 05/15/26
- AMP is WAC — 5/1/26
- AMP is WAC — 04/24/26
- AMP is WAC — 04/10/26
Categories
- 340B (67)
- Affordable Care Act (24)
- Alzheimer's (12)
- Biosimilars (33)
- Caught my eye (104)
- Cell and Gene (9)
- Chevron Deference (2)
- CMMI (31)
- Copay Accumulators (7)
- COVID (3)
- Drug Prices (60)
- Drug shortages (16)
- DTC (9)
- Employers (20)
- FDA (9)
- Generics (14)
- Health Equity (4)
- Healthcare Costs (43)
- Home Health (1)
- ICER (12)
- Importation (5)
- Inflation Reduction Act (70)
- Insulin (7)
- IP (3)
- Long term care (1)
- Medicaid (26)
- Medicare Advantage (28)
- Medicare Negotiation (69)
- Medicare Part D (80)
- Medicare Transaction Facilitator (5)
- Medicare Transaction Facilitator (12)
- Obesity (29)
- On the Horizon (1)
- Orphan Drugs (8)
- Pharmacy Benefit Managers (51)
- Preventative (5)
- Reference Pricing (27)
- State-based Reform (34)
- Supply Chain (9)
- Tariffs (3)
- Uncategorized (9)
- Utilization Management (14)
- Vaccines (10)
- Value (18)